Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Garmo

Showing results (201-210 of 261) with videos related to

Pageof 27
Sort By:
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BMC Immunology|September 7, 2021
Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS studyAida Santaolalla, Sam Sollie, Ali Rislan, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
Frontiers in Oncology|November 2, 2020
Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control StudyJonathan Parker, Danielle Crawley, Hans Garmo, et al.
BMC Molecular and Cell Biology|July 25, 2019
Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysisAida Santaolalla, Hans Garmo, Anita Grigoriadis, et al.
British Journal of Cancer|October 16, 2015
Serum lactate dehydrogenase and survival following cancer diagnosisWahyu Wulaningsih, Lars Holmberg, Hans Garmo, et al.
European Urology|July 17, 2017
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based StudyFrederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, et al.
Oncotarget|April 19, 2017
Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS StudyAndrew Yiu, Mieke Van Hemelrijck, Hans Garmo, et al.
International Journal of Cancer|June 4, 2017
The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohortPaul Nderitu, Cecilia Bosco, Hans Garmo, et al.
Pageof 27

Showing results (201-210 of 261) with videos related to

Sort By:
Pageof 27
Scandinavian Journal of Urology|May 13, 2022
Time to castration-resistant prostate cancer and prostate cancer death according to PSA response in men with non-metastatic prostate cancer treated with gonadotropin releasing hormone agonistsTiago M Bonde, Marcus Westerberg, Markus Aly, et al.
Ecancermedicalscience|February 20, 2018
A systematic review of the literature exploring the interplay between prostate cancer and type two diabetes mellitusDanielle Crawley, Florence Chamberlain, Hans Garmo, et al.
BMC Immunology|September 7, 2021
Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS studyAida Santaolalla, Sam Sollie, Ali Rislan, et al.
BJU International|January 15, 2019
Androgen deprivation therapy for prostate cancer and risk of dementiaDavid Robinson, Hans Garmo, Mieke Van Hemelrijck, et al.
Frontiers in Oncology|November 2, 2020
Use of Warfarin or Direct Oral Anticoagulants and Risk of Prostate Cancer in PCBaSe: A Nationwide Case-Control StudyJonathan Parker, Danielle Crawley, Hans Garmo, et al.
BMC Molecular and Cell Biology|July 25, 2019
Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysisAida Santaolalla, Hans Garmo, Anita Grigoriadis, et al.
British Journal of Cancer|October 16, 2015
Serum lactate dehydrogenase and survival following cancer diagnosisWahyu Wulaningsih, Lars Holmberg, Hans Garmo, et al.
European Urology|July 17, 2017
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease: Semi-ecologic, Nationwide, Population-based StudyFrederik Birkebæk Thomsen, Fredrik Sandin, Hans Garmo, et al.
Oncotarget|April 19, 2017
Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS StudyAndrew Yiu, Mieke Van Hemelrijck, Hans Garmo, et al.
International Journal of Cancer|June 4, 2017
The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohortPaul Nderitu, Cecilia Bosco, Hans Garmo, et al.
Pageof 27